M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
Scher
H
H
Oncology Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Herr
H
H
Sternberg
C
C
Fair
W
W
Bosl
G
G
Morse
M
M
Sogani
P
P
Watson
R
R
Darshaw
D
D
Reuter
V
V
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate